<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03709160</url>
  </required_header>
  <id_info>
    <org_study_id>18-1051</org_study_id>
    <nct_id>NCT03709160</nct_id>
  </id_info>
  <brief_title>Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure</brief_title>
  <acronym>DIVINE</acronym>
  <official_title>Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure. DIVINE STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro en Insuficiencia Cardiaca, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro en Insuficiencia Cardiaca, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study, consecutive patients, older than 18 years, of both genders will be
      included. The diagnosis of reduced Heart Failure (HfrEF) according to: Clinical pattern,
      laboratories and Cardiac imaging (ESC criteria). Treatment will be assigned in two groups:
      Bumetanide and another group will be received Indapamide. Each group received maximum
      tolerated dose for seven days with Clinical and labs evaluations will be every 48 hrs.
      (Face-to-face and/or telephone visits). Serum and urinary labs, EKGÂ´s, Echo will be
      evaluated. Daily in-home register will made. Final points were: Mortality, Urinary failure,
      Clinical Impairment, Hospital admissions, Oedema. (MUCHO). All patients will be followed for
      30 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In selected patients who sign informed consent with decompensation of cardiac failure by
      water congestion will be allocated in two groups: Bumetanide and the other Indapamide group.
      Each group will be given the maximum tolerated dose for seven days with clinical evaluations
      every 48 hours. (Face to face and/or telephone). Clinical variables, ECG and serum and urine
      laboratories will be assessed finally, patients will follow up for 30 days. To identify
      endpoints such as: mortality, urinary failure, clinical deterioration, hospital admissions,
      edema. (MUCHO).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2018</start_date>
  <completion_date type="Anticipated">October 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MORTALITY</measure>
    <time_frame>30 DAY</time_frame>
    <description>HEART FAILURE DEATH, CARDIOVASCULAR DEATH, OTHER DEATH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>REHOSPITALIZATION</measure>
    <time_frame>30 DAY</time_frame>
    <description>HEART FAILURE REHOSPITALIZATION, CARDIOVASCULAR REHOSPITALIZATION, OTHER REHOSPITALIZATION</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>URINARY FAILURE</measure>
    <time_frame>30 DAY</time_frame>
    <description>RENAL DETERIORATION (GFR &lt; 50%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLINICAL IMPAIRMENT</measure>
    <time_frame>30 DAY</time_frame>
    <description>FUNCTIONAL CLASS DETERIORATION</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OEDEMA</measure>
    <time_frame>30 DAY</time_frame>
    <description>ABNORMAL ACCUMULATION OF FLUID (SWOLLEN ANKLE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>BUMETANIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>we will administrated bumetanide at dosis: oral, 2mg each 8hours for seven day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INDAPAMIDE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>we will administrated indapamide at dosis:oral,1.5MG each 8hours for seven day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bumetanide 1 MG</intervention_name>
    <description>all patients will be taking the treatment recommended by heart failure guidelines</description>
    <arm_group_label>BUMETANIDE</arm_group_label>
    <arm_group_label>INDAPAMIDE</arm_group_label>
    <other_name>heart failure guidelines treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Older over 18 year 2. Both gender. 3. Patients are able to read, write and
             understand. 4.-Heart failure criteria:a) Clinical signs and symptoms b) serum
             NTP-proBNP: over 125pg/ml. or serum bnp: over: 35pg/ml. c) Left ventricular ejection
             fraction under 40% ( By any image study: echocardiogram, Tomography , MRI,Nuclear
             medicine.) 5. Commitment to participate in the follow-up of the present study.

        Exclusion Criteria:

          1. Pregnant or lactating women.

          2. Patients with deterioration of their clinical condition that warrant rapid attention
             by the emergency department.

          3. Patients with symptomatic hypotension by arterial pressure over; 90/50 mmHg.

          4. Symptomatic heart rate disorders: tachycardia greater than 120 beats per minute or
             bradycardia less than 50 beats per minute.

          5. Patients with respiratory impairment: by tachypnea (respiratory rate greater than 22
             per min), peripheral oxygen saturation less than 90%.

          6. Clinical signs or by methods of pleural effusion image that compromise the ventilatory
             mechanism.

          7. Hormonal thyroid decontrol (thyroid hormone profile outside the reference range)

          8. Serum glucose numbers greater than 140mg/DL and/or glycosylated hemoglobin greater
             than 6.5%.

          9. Renal damage characterized by serum creatinine numbers greater than 1.5 mg/DL.

         10. Alteration of the hepatic test: serum aspartate aminotransferase and/or serum alanine
             aminotransferase by levels greater than three times the upper limit of reference.

         11. Alterations in serum electrolytes (by sodium greater 135 mmol/L or less 145 mmol;
             Potassium less than 3.5 mmol/L or higher 5.35 mmol/L)

         12. Intolerance or allergy recognized for any diuretic.

         13. Comorbidities that prevent the follow-up of treatment: (Alcoholism, drug addiction,
             psychiatric disorders)

         14. Positive serology carriers for Hepatitis (B, C) HIV.

         15. Acute myocardial infarction (with and without elevation) in the last three months.

         16. History of vascular (ischemic or hemorrhagic) brain disease in the last three months.

         17. Carriers of acute inflammatory and/or immunologic disease in the last three months
             (e.g. Active Lupus etc.)

         18. Active myocarditis in the last three months

         19. History of Prostatism, or recognized prostatic alterations, that impede voiding flow.

         20. Terminal cancer

         21. Blunt physical and cognitive deterioration that prevents optimal follow-up.

         22. Cultural barriers involving limitation of communication (languages, dialects, reading
             and writing, etc.).

         23. Not to sign informed consent

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EDUARDO CHUQUIURE-VALENZUELA, MD MSc</last_name>
    <role>Study Director</role>
    <affiliation>HEART FAILURE CENTER INSTITUTO NACIONAL DE CARDIOLOGIA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Insuficiencia Cardiaca Instituto Nacional de Cardiologia</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHUQUIURE-VALENZUELA EDUARDO, MD, MSc</last_name>
      <phone>+5215554017407</phone>
      <email>echuquiurev@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>EDUARDO CHUQUIURE-VALENZUELA, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>OSCAR FISCAL-LOPEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, GonzÃ¡lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. Erratum in: Eur Heart J. 2016 Dec 30;:.</citation>
    <PMID>27206819</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro en Insuficiencia Cardiaca, Mexico</investigator_affiliation>
    <investigator_full_name>EDUARDO CHUQUIURE-VALENZUELA MD MSc FACC</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individua participant data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>will be available from the publication up to 10 years after the publication</ipd_time_frame>
    <ipd_access_criteria>Upon request addressed to principal investigator, specifying the Statistical Analysis Plan specific points you want to review</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

